TG THERAPEUTICS, INC. (TGTX) Q3 2025 10-Q Quarterly Report
TG THERAPEUTICS, INC. (TGTX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
TG THERAPEUTICS, INC. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: post-marketing requirements for BRIUMVI including long-term safety studies and pediatric/pregnancy evaluation triggered by FDA approval conditions
- • Most updated risk: commercialization challenges due to expanding global operations; BRIUMVI launched in Europe Feb 2024 with risks in third-party partnerships impacting sales control
- • Key regulatory risk: ongoing compliance with cGMP, GCP, GLP and risk of FDA-imposed labeling changes, REMS, product recalls, or approval suspension after unforeseen side effects
- • Near-term operational risk: intense competition from larger pharma with greater R&D and commercialization resources could limit BRIUMVI market share and revenues
- • Financial risk: reimbursement challenges and pricing pressures from U.S. government healthcare programs like Medicaid rebates and 340B discounts may reduce net pricing and revenues
TG THERAPEUTICS, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$162M
▲ +92.8% YoY▲ +14.6% QoQ
Net Income
$391M
▲ +9974.6% YoY▲ +1286.8% QoQ
Operating Margin
18.2%
▲ +334bp YoY▼ -653bp QoQ
Net Margin
241.7%
▲ +23710bp YoY▲ +22176bp QoQ
ROE
64.4%
Total Assets
$1.0B
EPS (Diluted)
$2.42
▲ +7966.7% YoY▲ +1323.5% QoQ
Operating Cash Flow
-$23M
▼ -89.7% YoY▼ -411.4% QoQ
Source: XBRL data from TG THERAPEUTICS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on TG THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.